Version 2 (modified by 4 years ago) ( diff ) | ,
---|
LhARA Steering Group meeting #3
3rd July 2020 10:00 GMT
Agenda
- Notes of last meeting and actions arising:
- KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
- Ongoing. Need to step up the priority of this activity as we prepare the EPSRC proposal.
- KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
- Stands. This meeting is necessary and, probably, should include Strathclyde and Belfast.
- KL/KK to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
- Stands. Agenda item.
- KL Send out diary invitation straight away to get it into the diary.
- Done.
- KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
- [raw-attachment:2020-07-03-SGMeeting.pdf Project Managers report: AK
- Discussion of SG composition: KL/All
- EPSRC Transformative Healthcare Technologies call: KL/All
- Dealing with feedback from our 2019 submission:
"Engagement with patients, clinicians and industry could have been strengthened"- Patient engagement:
- Actions taken to date;
- Need for local action by partner;
- Subsequent coordination
- Patient engagement:
- Clinician engagement:
- Actions taken to date;
- Need for local action by partner;
- Subsequent coordination
- Industrial engagement:
- Actions taken to date;
- Discussion of next steps
- Slides to initiate discussion of:
- Scope;
- Initial discussion of work packages;
- Stakeholders from whom we should be seeking support;
- Next steps discussion
- Dealing with feedback from our 2019 submission:
- Follow-up Discussion of dedicated advanced diagnostics and instrumentation for the in vitro and in vivo end stations: KL/all
- DONMs
- 04 Sep 2020; 10:00 BST
- AoB
Attachments (1)
- 2020-07-03-Progress-update.pdf (391.6 KB ) - added by 4 years ago.
Download all attachments as: .zip
Note:
See TracWiki
for help on using the wiki.